APELLIS PHARMACEUTICALS, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 49.14 USD | +0.86% |
|
+2.69% | -17.61% |
Presenter SpeechChris Howerton (Analysts)Okay. Good afternoon, everybody. Thank you so much fo...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system. SYFOVRE (pegcetacoplan injection) is the Companyâs approved treatment for geographic atrophy secondary to age-related macular degeneration (GA). Its EMPAVELI (pegcetacoplan), is for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Its Aspaveli (pegcetacoplan) for the treatment of adults with PNH who are anemic after treatment with a C5 inhibitor for at least three months. Systemic pegcetacoplan has also been approved for the treatment of PNH in Japan, Saudi Arabia, Australia, the United Kingdom and other jurisdictions. Systemic pegcetacoplan is marketed under the trade name EMPAVELI in the United States, Saudi Arabia and Australia and Aspaveli in the European Union, Japan and United Kingdom.
Sector
Pharmaceuticals
Calendar
2024-05-06
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
48.72
USD
Average target price
82.01
USD
Spread / Average Target
+68.33%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -16.81% | 5.87B | |
| -2.86% | 87.37B | |
| +4.08% | 41.01B | |
| -20.73% | 28.08B | |
| +53.36% | 24.72B | |
| -3.79% | 17.47B | |
| -42.09% | 11.69B | |
| -18.12% | 11.6B | |
| -12.10% | 11.56B | |
| +1.57% | 8.44B |
- Stock Market
- Equities
- APLS Stock
- News Apellis Pharmaceuticals, Inc.
- Transcript : Apellis Pharmaceuticals, Inc. Presents at 2022 Jefferies Global Healthcare Conference, Jun-09-2022 04
